Che-Ming Teng Selected Research

denbinobin

1/2013	Denbinobin induces human glioblastoma multiforme cell apoptosis through the IKKα-Akt-FKHR signaling cascade.
8/2011	Denbinobin suppresses breast cancer metastasis through the inhibition of Src-mediated signaling pathways.
7/2011	The inhibition of angiogenesis and tumor growth by denbinobin is associated with the blocking of insulin-like growth factor-1 receptor signaling.
5/2009	Apoptosis signal-regulating kinase 1 mediates denbinobin-induced apoptosis in human lung adenocarcinoma cells.
11/2008	Denbinobin induces apoptosis by apoptosis-inducing factor releasing and DNA damage in human colorectal cancer HCT-116 cells.
2/2008	Denbinobin induces apoptosis in human lung adenocarcinoma cells via Akt inactivation, Bad activation, and mitochondrial dysfunction.
1/2005	Denbinobin-mediated anticancer effect in human K562 leukemia cells: role in tubulin polymerization and Bcr-Abl activity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Che-Ming Teng Research Topics

Disease

57	Neoplasms (Cancer) 07/2021 - 02/2003
14	Prostatic Neoplasms (Prostate Cancer) 02/2012 - 09/2002
11	Breast Neoplasms (Breast Cancer) 01/2020 - 06/2004
10	Hepatocellular Carcinoma (Hepatoma) 01/2017 - 03/2005
9	Colorectal Neoplasms (Colorectal Cancer) 11/2015 - 07/2008
7	Leukemia 04/2017 - 05/2004
6	Lung Neoplasms (Lung Cancer) 07/2021 - 07/2007
6	Neoplasm Metastasis (Metastasis) 03/2013 - 11/2007
5	Inflammation (Inflammations) 10/2014 - 07/2002
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2014 - 06/2007
4	Hypoxia (Hypoxemia) 09/2015 - 09/2009
4	Adenocarcinoma of Lung 08/2012 - 02/2008
3	Pancreatic Neoplasms (Pancreatic Cancer) 01/2019 - 08/2013
3	Hyperplasia 01/2016 - 06/2003
3	Vascular System Injuries 01/2016 - 06/2003
3	Renal Cell Carcinoma (Grawitz Tumor) 01/2015 - 01/2012
3	Thrombosis (Thrombus) 08/2013 - 09/2006
2	Body Weight (Weight, Body) 01/2017 - 01/2012
2	Ovarian Neoplasms (Ovarian Cancer) 01/2017 - 01/2016
2	Carcinogenesis 08/2012 - 01/2011
2	Kidney Neoplasms (Kidney Cancer) 01/2012 - 04/2010
2	Cardiovascular Diseases (Cardiovascular Disease) 09/2009 - 12/2003
2	Mitochondrial Diseases (Mitochondrial Disease) 02/2008 - 01/2005
2	Acute Promyelocytic Leukemia 10/2005 - 01/2005
1	Polyploidy 01/2016
1	Carcinoma (Carcinomatosis) 01/2016
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 07/2015
1	B-Cell Lymphoma (Lymphoma, B Cell) 03/2015

Drug/Important Bio-Agent (IBA)

10	Proteins (Proteins, Gene)FDA Link 07/2021 - 01/2005
10	Histone Deacetylase InhibitorsIBA 01/2019 - 01/2011
10	Pharmaceutical PreparationsIBA 04/2017 - 05/2005
7	TubulinIBA 08/2015 - 09/2002
7	denbinobinIBA 01/2013 - 01/2005
7	Hormones (Hormone)IBA 02/2012 - 02/2004
6	Histone Deacetylases (Histone Deacetylase)IBA 01/2016 - 01/2011
5	Antineoplastic Agents (Antineoplastics)IBA 01/2017 - 07/2007
4	3- (1- benzenesulfonyl- 2,3- dihydro- 1H- indol- 5- yl)- N- hydroxyacrylamideIBA 01/2019 - 01/2012
4	dendrophenolIBA 01/2017 - 07/2008
4	NF-kappa B (NF-kB)IBA 01/2012 - 10/2005
4	evodiamineIBA 09/2009 - 05/2004
4	IndazolesIBA 01/2006 - 12/2003
3	Cardiac GlycosidesIBA 01/2017 - 09/2002
3	Phosphotransferases (Kinase)IBA 01/2017 - 07/2011
3	CaspasesIBA 01/2016 - 02/2008
3	Cadherins (E-Cadherin)IBA 07/2014 - 01/2011
2	Notch1 ReceptorIBA 01/2020 - 01/2016
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2019 - 08/2013
2	Protein Kinases (Protein Kinase)IBA 01/2017 - 07/2008
2	Antimitotic AgentsIBA 01/2016 - 02/2008
2	3,6- bis(5- chloro- 2- piperidyl)- 2,5- piperazinedioneIBA 01/2016 - 08/2013
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2015 - 08/2013
2	YXM110IBA 09/2015 - 09/2013
2	Vincristine (Oncovin)FDA LinkGeneric 07/2015 - 09/2002
2	Vorinostat FDA Link 07/2015 - 01/2011
2	EnzymesIBA 11/2014 - 02/2010
2	matrigelIBA 10/2014 - 07/2011
2	CarrageenanIBA 10/2014 - 07/2013
2	Histones (Histone)IBA 07/2014 - 01/2014
2	Caspase 3 (Caspase-3)IBA 03/2014 - 02/2008
2	Type II DNA Topoisomerases (Topoisomerase II)IBA 01/2014 - 01/2012
2	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2014 - 06/2007
2	antofineIBA 08/2012 - 07/2011
2	cryptopleurineIBA 08/2012 - 07/2011
2	neotanshinlactoneIBA 07/2012 - 03/2010
2	aciculatinIBA 01/2012 - 01/2012
2	Thrombin FDA Link 04/2011 - 09/2006
2	CytokinesIBA 01/2010 - 05/2005
2	2-phenyl-4-oxohydroquinolineIBA 02/2008 - 06/2007
2	bromovulone IIIIBA 10/2005 - 04/2004
2	ProstaglandinsIBA 10/2005 - 01/2005
2	Paclitaxel (Taxol)FDA LinkGeneric 05/2005 - 09/2002
2	AlkaloidsIBA 01/2005 - 05/2004
2	Ouabain (G Strophanthin)IBA 02/2004 - 09/2002
2	AndrogensIBA 02/2004 - 09/2002
1	BenzamidesIBA 07/2021
1	AfatinibIBA 07/2021
1	quinolineIBA 04/2017
1	lanatoside CIBA 01/2017
1	Digoxin (Digitek)FDA LinkGeneric 01/2017
1	Anti-Arrhythmia AgentsIBA 01/2017
1	MicroRNAs (MicroRNA)IBA 11/2016
1	Small Interfering RNA (siRNA)IBA 04/2016
1	integrin-linked kinaseIBA 04/2016
1	Estrogens (Estrogen)FDA Link 04/2016
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2016
1	LigandsIBA 01/2016
1	3- (1- (4- methoxybenzenesulfonyl)- 2,3- dihydro- 1H- indol- 5- yl)- N- hydroxyacrylamideIBA 01/2016
1	Cisplatin (Platino)FDA LinkGeneric 01/2016
1	Carrier Proteins (Binding Protein)IBA 09/2015
1	Eukaryotic Initiation Factor-4EIBA 09/2015
1	diphenyl (biphenyl)IBA 08/2015
1	compound 21IBA 08/2015
1	BenzenesulfonamidesIBA 08/2015
1	dactolisibIBA 02/2015
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 02/2015

Therapy/Procedure

17	Therapeutics 01/2017 - 09/2002
4	Drug Therapy (Chemotherapy) 04/2017 - 01/2005
2	Oral Administration 04/2017 - 01/2016
2	Radiotherapy 11/2014 - 03/2013
2	Aftercare (After-Treatment) 01/2012 - 10/2005